Business Context and Reporting Period
This Form 8-K Current Report was filed by Compass Diversified Holdings (CODI) and Compass Group Diversified Holdings LLC on August 12, 2008, regarding events occurring on August 8, 2008. The filing details a strategic transaction involving the acquisition of equity in Anodyne Medical Device, Inc. ("Anodyne") from Hollywood Support Partners, LLC ("Hollywood").
Key Financial Metrics and Transaction Details
The Company consummated a Stock Purchase and Option Agreement to acquire shares of Anodyne. The aggregate purchase price was $7,092,784.69. The transaction structure included:
- Assets Acquired: 67,067 shares of Series B Common Stock and 28,497 shares of Series A Preferred Stock of Anodyne.
- Payment Method 1 (Debt Cancellation): Cancellation of a promissory note owed by Hollywood to the Company. The outstanding principal and accrued interest totaled $6,892,784.69. The note carried a 13.0% payment-in-kind interest rate, dated February 15, 2006, and due August 15, 2008.
- Payment Method 2 (Option Grant): Granting of an option valued at $200,000 to Hollywood. This option allows Hollywood to purchase 47,690 shares of Series B Common Stock from the Company at a strike price exceeding the price paid by the Company.
The filing does not provide specific revenue, profit, cash flow, or margin data for the reporting period, as this is a current report focused on a specific event rather than a periodic financial statement.
Material Changes and Management Commentary
Concurrent with the transaction, Mark Bidner, the managing member of Hollywood and Chairman of Anodyne's Board, resigned from his roles as Chief Executive Officer, President, and Secretary of Anodyne. He will continue to serve as Chairman of the Board. The transaction represents a shift in ownership structure and management control for the Anodyne investment.
Risks and Contingencies
The Agreement includes customary representations and warranties regarding Hollywood's organization, authority, lack of conflicts, legal proceedings, and ownership of the shares. The filing does not disclose specific new risks or contingencies beyond the standard terms of the stock purchase agreement.
Key Facts for Investor Verification
- Verify the fair value of the $200,000 option granted to Hollywood and its impact on the Company's equity.
- Confirm the valuation of Anodyne Medical Device, Inc. implied by the transaction price.
- Assess the impact of the debt cancellation ($6.89 million) on the Company's balance sheet and interest income recognition.
- Review the terms of the option strike price to understand the potential dilution or future cash flow implications.
- Monitor the operational performance of Anodyne following the resignation of its CEO and President.